drugset / Trial / NCT05757544

Safety and Efficacy Study of IV Ganaxolone as Adjuvant Therapy for Established Status Epilepticus (ESE)

NCT05757544

Phase 2 Withdrawn Marinus Pharmaceuticals
RandomizedSequentialTriple-blindTreatment

Summary

This study is designed to optimize the dosing regimen and evaluate the preliminary safety and efficacy of Intravenous (IV) ganaxolone as adjuvant therapy for participants with ESE receiving initial IV antiepileptic drug (AED) according to currently practiced standard of care (SOC). The study will be composed of 2 phases: an initial, open-label, dose optimization phase followed by IV ganaxolone versus placebo double-blind phase.

Timeline

Start
2023-04-01
Primary completion
2026-02
Completion
2026-02

Drugs

EvaluationDrugModalityDoseRoute
Subject Ganaxolone Small molecule Intravenous

Indications

No indication recorded.